CClinicalTrials.gg
CompletedNCT01745523Updated Mar 10, 2015

Use of a Synthetic Macromolecule (Hydroxypropyl Cellulose ) and Trehalose as Additives for Oocyte Vitrification

An interventional study of Synthetic macromolecule HPC and trehalose and SSS containing HSA and sucrose in Infertility, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA. Completed at 1 site in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2015-03-10.

Sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This study is aimed to evaluate the use of Hydroxypropyl Cellulose (HPC) as substitute for the traditional protein supplement (Synthetic Serum Substitute; SSS) and Trehalose as substitute for the most widely used sugar (Sucrose) in the vitrification solutions employed for oocyte vitrification.

Read the detailed description

Vitrification involves the transformation of an aqueous solution into a very viscous solid avoiding ice formation. To achieve this, the vitrification protocols include high concentrations of cryoprotectants dissolved in a base medium supplemented with serum rich in protein. Traditionally available preparations contains human albumin (HSA). The most commonly used in vitrification solutions is the synthetic serum replacement (SSS) consisting of synthetic glycoporoteins and HSA. The replacement of human albumin by other fully synthetic components enables compliance with the European directives for classification of Class III medical device in accordance with the Manual for the Classification of Medical Devices in the regulatory framework of the European community, and therefore these media have the European CE conformity marking (Directive 93/42/EEC). According to European regulations, Class III medical devices are subject to special supervision and require certification exam or design type examination by a notified body. Commercial media supplied by Kitazato supplies ® (Tokyo, Japan) to be used in this study have been submitted to the whole process of evaluation and certification by the notified body BSI0086. Because of physical properties of hydroxypropyl cellulose (HPC), fully synthetic macromolecule, including the ability to form a viscous gel at low temperatures, this macromolecule has been proposed as a substitute for human origin albumin (HSA). Another necessary component of vitrification media is sucrose, which acts as an osmotic agent. Trehalose, a disaccharide present in nature is used by certain species to survive extreme conditions, being able to remain vitrified for years. This sugar has also been employed previously in cryobiology in some vitrification protocols. We have tested HPC and threhalose for oocytes vitrification in a pilot study, showing that no impairment in the survival rates, embryo development and pregnancy rates. The current study is a prospective randomized trial aimed to assess the outcome of ovum donation cycles conducted with vitrified oocytes using HPC and trehalose versus oocytes vitrified using traditional available solutions containing HAS and sucrose.

02

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Oocyte vitrification
  • survival rate
  • egg banking
  • ovum donation
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's enrollment of 440 is above the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA is the lead sponsor of 70 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

Donors:

  • \< 35 years old
  • Normal physical and gynecological examinations
  • No family history of hereditary or chromosomal diseases.
  • Normal karyotype
  • Negative screening for sexually transmitted diseases.

Oocyte recipients:

  • Oocyte recipients \< 50 years old
  • Body mass index\< 30
  • \< 2 previous IVF failures
  • No severe male factor
  • No recurrent miscarriage
  • No hidrosalpinx
  • No myoma
  • No adenomyosis
  • No AMH alterations

Exclusion criteria

Exclusion Criteria:

Donors and recipients not meeting inclusion criteria

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Vitrified oocytes using HPC+Trehalose

    Oocytes are vitrified using the synthetic macromolecule HPC and trehalose

    Procedure: Synthetic macromolecule HPC and trehalose

  • Active comparator
    Vitrified oocytes using SSS+ Sucrose

    Oocytes are vitrified using the SSS containing HSA and sucrose

    Procedure: SSS containing HSA and sucrose

Interventions

  • ProcedureSynthetic macromolecule HPC and trehalose

    Oocytes are vitrified using the synthetic macromolecule HPC and trehalose

  • ProcedureSSS containing HSA and sucrose

    • Oocytes are vitrified using the SSS containing HSA and sucrose

06

What researchers measure

Primary outcomes

  1. Survival after oocyte vitrification using cryoprotective solutions containing hiroxipropilcelulosa (HPC) and trehalose.

    After warming and embryo transfer. Survival will be evaluated morphologically two hours after warming.

    Time frame: >2 hours

Secondary outcomes

  1. Embryo development

    Time frame: From time of thawing until pregnancy outcome (0-9 months)

07

Study locations

1 site
  • IVI Valencia
    Valencia, 46117, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01745523
Lead sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Responsible party
Ana Cobo (Cryobiology Unit Director at IVI Valencia, Instituto Valenciano de Infertilidad, IVI VALENCIA) — Principal investigator
First posted
Dec 10, 2012
Start date
Nov 2012
Primary completion
Apr 2014
Completion
Oct 2014
Last update
Mar 10, 2015

Study contacts

Ana Cobo, PhD
principal investigator · IVI Valencia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion